Abstract: This study explored the potential of chitosan/hydroxyapatite (HA) composites to act as a controlled drug delivery system by developing functional scaffolds with a gradient of structure and drug concentration. Firstly, a porous composite scaffold was prepared and tetracycline hydrochloride (TCH) was impregnated in the scaffold as a model drug. The pore size of the scaffold was negatively dependent on the HA content and ranged about 40-250 lm. Subsequently, a porous chitosan/HA composite layer without drug was coated on the scaffold to create a gradient drug concentration in the specimen. The in vitro drug-release test demonstrated that the porous layer without drug on the outer surface of the scaffold significantly reduced the initial burst of drug release and extended the release period. Finally, a successive and dense chitosan/HA composite layer endowed the scaffold with a sustained, drugrelease pattern without any initial drug burst. These findings confirmed the high effectiveness of the hybrid scaffolds in regulating the release of drugs, and hence their capability to serve as a temporary drug carrier in tissue regeneration. These functional scaffolds also have potential application to the delivery of some bioactive molecules such as growth factors. '
INTRODUCTION
Chitosan/hydroxyapatite (HA) composites, one of the most promising candidates for hard tissue regeneration, have undergone extensive laboratory and clinical evaluations. [1] [2] [3] However, their in vivo utilization usually requires preventive antibiotic therapy to avoid the development of postoperative problems such as infections, pain, and loosening between host tissues and implants. Moreover, the local delivery of some bioactive molecules, including various growth factors and other proteins, is also highly desirable for the composites to stimulate tissue healing processes. 4, 5 Based on this, drug-loaded chitosan/HA composites hold great promise for improving the therapeutic efficiency in tissue regeneration with the aid of functional drugs. At implantation sites, the potential exists for drugs entrapped within the composites to be delivered in a controlled manner over a period of treatment, thus alleviating the postoperative complications as well as promoting the regeneration of new tissues. In recent years, however, only a few groups have developed the chitosan/HA composites as a drug delivery device for hard tissue engineering. 6 The objective of this work was to construct a threedimensional (3D), chitosan/HA hybrid scaffold for controlled drug-release. The coprecipitated chitosan/HA composites were first processed into a porous scaffold by molding and freeze-drying. Tetracycline hydrochloride (TCH), which was selected as a model drug, was homogeneously entrapped within the composites scaffolds. The phases and morphological features of the obtained scaffolds were investigated by X-ray diffraction (XRD) and scanning electron microscopy (SEM). Their feasibility as a drugdelivery system was assessed by an in vitro, drug-release test.
The gradient principle offers great flexibility in regulating the delivery of drugs and is consequently suitable for many types of system. 7, 8 The entrapment of drugs in deep layers of the scaffolds compensates for the traveling distance of the drugs during the dissolution process, thus resulting in the desirable production of a linear, zero-order pattern of drug release. 9, 10 Considering the above, we explored a gradient-based strategy to tailor the drug-release profiles of the porous chitosan/HA composite scaffolds by designing various material formulations. Two kinds of functional scaffold were achieved via successive coating steps around the scaffolds with nondrug-loaded, porous, and dense layers. The first porous layer was expected to create a concentration gradient of drugs between the inner and outer scaffolds, and the second dense layer to offer a further structural gradient between the two layers. This design optimization was anticipated to provide the chitosan/HA composite scaffolds with the capability to deliver drugs in a controlled manner.
MATERIALS AND METHODS
Chitosan powder (75-85% deacetylation, 200-800 cP) was commercially obtained from Sigma-Aldrich and purified before use. Calcium hydroxide [Ca(OH) 2 ], phosphoric acid (H 3 PO 4 ), TCH, and all other reagents were also acquired from Sigma-Aldrich. Phosphate-buffered saline (PBS) tablets were dissolved in distilled water to prepare the drugrelease medium.
Preparation of TCH-Loaded Chitosan/HA Composite Scaffolds
Chitosan was purified by dissolution in 1% acetic acid and subsequent re-precipitation with 10% NaOH. We have previously described the procedure for preparing the chitosan/ HA composites in detail. 11 Briefly, chitosan and HA were coprecipitated at 378C by simultaneously adding the chitosan-acetic acid/H 3 PO 4 mixture and a stoichiometric amount of Ca(OH) 2 aqueous solution (Ca/P 5 1.67) into 0.2M Tris [Tris (hydroxymethyl) aminoethane]-HCl buffer (pH 9.0) under vigorous stirring. After 18 h of additional stirring at 378C, the precipitate was sufficiently centrifuged and washed with water. The final centrifugation was performed at 3000 rpm for 30 min to remove most of the water in the precipitate. This precipitate without drying (denoted as wet precipitate) was used in the later experiments to prepare the drug-loaded scaffolds as well as the drug-free coating layers.
To prepare the drug-loaded chitosan/HA scaffolds, the as-obtained precipitate was adequately mixed with an appropriate amount of TCH powder to produce a uniform paste. Subsequently, the paste was molded in a plastic bottle and freeze-dried for 36 h in the dark. Cylindrical scaffolds with a diameter of 10 mm were finally obtained, without any serious shrinkage or deformation. As TCH is sensitive to light and heat, the TCH-loaded scaffolds were kept in the dark at 48C until used. The theoretical weight percentages of HA in the composites were 20 and 40% (denoted hereafter as CTS-20% HA and CTS-40% HA, respectively), and the TCH loading within the scaffolds was fixed at 10% w/w with respect to CTS 1 HA. For comparison, pure chitosan scaffolds were also prepared under the same conditions.
Functionally Gradient Scaffolds
Based on the aforementioned porous, drug-loaded scaffolds, two kinds of functional composite scaffold with gradient structure or drug concentration were designed to control the TCH release rate. Firstly, a suitable size of the plastic bottle was chosen as a mold, and then covered with a layer of the drug-free precipitate on the bottom. The drug-loaded scaffolds were cut cross-sectional into 1-cm-high cylinders and centrally placed on the precipitate. Subsequently, the gap between the mold and the scaffold was carefully filled with the precipitate. Special care was taken during this process to avoid large air bubbles in the coating layer and allow the precipitate to settle densely. After the scaffold was entirely covered with a drug-free layer of the wet precipitate, it was freeze-dried for 36 h at 2608C to obtain a 1-mm-thick porous coating layer. The thickness of the coating layers could be controlled by changing the size of the molds. A similar procedure was used to fabricate the second kind of functional scaffold. Typically, a dense, 2-mmthick coating layer without drugs was successively prepared by surrounding the first functional scaffold with the drugfree precipitate and air-drying in the dark for 36 h at room temperature under a dust-free hood. The core and shell of the two functional scaffolds were prepared at the same composition of chitosan and HA. In this study, we present an example taken from the CTS-20% HA composites.
Characterizations and Drug-Release Tests
The cross-sectional microstructure of the scaffolds was characterized by SEM (JSM-5410LV, JEOL, Japan). The phase analysis was performed on the freeze-dried samples with XRD (M18XHF-SRA, Mac Science, Japan).
For the drug-release test, the samples were immersed in plastic tubes containing 50 mL of PBS solution (0.01M, pH 7.4) which was replaced daily. Subsequently, the tubes were incubated in a water bath at 378C without stirring. At selected intervals, 2-mL-aliquots were withdrawn and analyzed using a ultra-violet (UV) spectrophotometer (UV-1700, Schimadzu, Japan) at an optimal wavelength of 362 nm. An equal volume of fresh medium was added to the incubation solution. The release amount of TCH was calculated from an absorbance-concentration calibration curve which was constructed over the concentration range from 1 to 100 lg mL 21 , and the cumulative TCH release was represented after being normalized to its initial amount in the scaffolds, which was obtained by multiplying the weight of the preobtained porous scaffold by the theoretical weight percentage of TCH. The drug-release test was performed in triplicate, and data were reported as mean 6 standard deviation (SD).
RESULTS

Morphology and Composition of Scaffolds
The TCH-mixed composite paste had a good shape-forming ability. After the freeze-drying process, the drug-loaded composite scaffold displayed a regular cylindrical shape and a uniform yellow color throughout the scaffold, as shown in Figure 1(a) . No obvious deformation occurred in the final chitosan/HA scaffolds of various compositions.
Moreover, the obtained scaffolds exhibited good cutability, thereby enabling various clinical requirements to be met by cutting the scaffolds into suitable shapes and sizes. Figures 1(b-d) show the cross-sectional SEM morphologies of the chitosan and chitosan/HA hybrid scaffolds with 10% drug loading. It was observed from Figure 1 (b) that the TCH-containing chitosan scaffold exhibited a welldeveloped porous structure, consisting of open pore channels and an interconnected framework. Most of these pores had a cylindrical microstructure with an average pore diameter of about 250 lm. The scaffolds composed of chitosan and 20 wt % HA exhibited a framework that maintained the continuously porous feature and good interpore connectivity of the control chitosan scaffolds [ Figure 1(c) ]. However, the pore size of the CTS-20% HA composite scaffold was significantly reduced to be 100 lm. The cross-section of the CTS-40% HA scaffold also displayed a highly porous structure containing a set of irregular pores, as shown in Figure 1(d) . The pore size of this scaffold was further decreased to about 40 lm due to the increased HA content.
The phase compositions of the chitosan/HA scaffolds were investigated using XRD analysis. Figure 2 shows the XRD patterns of the CTS-20% HA composite scaffolds before and after drug loadings. Chitosan produced a strong diffraction pattern at around 208, indicating its good crystallization in the composites. HA was identified as the only inorganic phase in the scaffolds, with the characteristic diffraction of (002) at 25.88 and an overlapped diffraction of (300), (211), and (112) at 31.88. The broadening and overlapping of these diffraction peaks in the XRD pattern were indicative of the low crystallinity and ultra-fine size of the HA crystals. 11, 12 There were no obvious differences in the diffractogram of the CTS-20% HA composites when 10% TCH was entrapped. This indicated that the incorporation of TCH exerted little influence on the structure and crystallinity of the chitosan/HA composites.
Drug-Release Behavior of the Scaffolds with Different Compositions
The effect of HA content on the TCH release from the porous scaffolds was firstly investigated in PBS buffer solution over a period of 5 days. Figure 3 presents the cumulative drug-release profiles of the scaffolds with different compositions. All the scaffolds displayed a triphasic release pattern of an initial burst, followed by a long period of sustained release, and finally an erosion phase, as often described in the literature. 13, 14 During the first 2 h of the test, the drugrelease rate was so fast that about 30% of the TCH was released from the scaffolds. This rate was nearly independent on the sample composition. Such a burst effect was mostly due to the abrupt release of the exposed drug on the surface of the scaffolds. During a follow-up period of 72 h, the TCH release from these scaffolds continued at a much slower release rate via diffusion of the entrapped drug through the porous network. The hybrid composite scaffolds were apparently more effective in releasing the drugs in a controlled way than their chitosan equivalents. The release rate during this period was observed to be in the order of chitosan [ CTS-20% HA [ CTS-40% HA scaffolds, clearly indicating a decreasing TCH release rate with increasing HA content. After this period, the release rate of all three samples tended to be very slow (close to zero). An almost complete drug release of 96% was achieved for the pure chitosan scaffolds within 72 h, whereas about 92 and 84% of the loaded drug in the hybrid system was released from the CTS-20% HA and CTS-40% HA scaffolds at 72 h, rising to 93 and 86% at 120 h, respectively.
Drug-Release from the Functional Gradient Scaffolds
Two novel types of functional scaffold were fabricated, as illustrated in Figure 4 . The first formulation consisted of a porous drug-loaded core and a porous drug-free coating layer (1 mm) to create a concentration gradient of drugs between the core and shell of the scaffolds. To prepare the second type, a dense layer was successively deposited as the surrounding skin of the samples via the molding and air-drying processes, thereby generating a structure gradient between the inner and outer layers around the core. As indicated in Figure 4 , the coatings were uniformly formed onto the surface of the porous core in the present system. Moreover, both types showed an integrated structure between the core and shell without any severe delamination.
The transverse sections of the second functional scaffolds were examined using SEM, and their morphologies are presented in Figure 5 . The core scaffolds developed an open-pore structure [ Figure 5(a) ], whereas the shell seemed to be significantly densified with negligible pores [ Figure 5(c) ]. Boundary between the porous core and the dense shell is well observed in Figure 5 (b). The morphological difference between the core and shell of the scaffolds was attributed to their different drying methods. The core and shell parts were tightly bonded with each other so as to form an integral scaffold, which further confirmed our observation in Figure 4 .
The drug-release patterns of the two types of functional scaffold were investigated to explore the regulation of such gradient coatings on their drug-release behavior. As shown in Figure 6 , the first type of scaffold, containing a single porous coating layer, had a significantly decreased burst release, with a drug-release value of only about 5% during the first 2 h of assays. After this initial burst, a relatively slower and steadier drug release was achieved with the porously coated scaffolds than with the porous scaffolds without coating. Moreover, the porous coating secured delivery of TCH for up to 240 h. Although the porous structure of the outer layer offered sufficient channels for rapid drug diffusion from the inner part, the diffusion path length of the drugs was greatly increased due to the presence of the coating layer, thereby decreasing the burst effect and prolonging the release kinetics. For the second type of functional scaffold, no drug was released during the first 12 h of assays, probably owing to the difficulty of drug diffusion through the dense layer as well as the long diffusion length of the drugs. For practical application, this period could be avoided by preimmersing the scaffolds in PBS for 12 h before implantation, after which the drug release from the scaffolds exhibited a nearly zero-order kinetic, which was characterized by a slower, but approximately linear release over 240 h without initial drug burst.
DISCUSSION
This study presents a simple but efficient method to prepare TCH-entrapped, chitosan/HA composite scaffolds with a porous structure. The novel technique involved coprecipitation, molding, and consequent freeze-drying. Compared with the conventional mixing method wherein the preobtained inorganic powder was dispersed into the viscous polymer solution followed by a lyophilization step, 15 ,16 the present approach was more efficient in obtaining a nanocomposite with biomimetically structural and morphological features. 17 Moreover, a considerable amount of TCH powder could be incorporated into the centrifuged chitosan/ HA composite precipitate by mixing them together before molding, thereby ensuring the high drug-loading efficiency of the resultant scaffolds.
The macro-and micro-pores in the TCH-loaded scaffolds were considered to have formed during the lyophilization process. During lyophilization, which is one of the most efficient methods to create porosity in a scaffold, 18 ice crystals are sublimated in a vacuum-drying process, thereby allowing the scaffold to maintain its original structure in a frozen state. 19 In this case, the degree of centrifugation in the present system was also expected to greatly influence the final pore configurations of the scaffolds as it represented the water content in the precipitate, that is, the final volume of ice crystals in the frozen scaffold. Although the centrifugation and lyophilization processes were carried out at fixed conditions in this study, it should be possible to further tailor the pore size and porosity of the scaffolds by changing those conditions to match a wide range of practical applications.
When used as a tissue engineering material, these porous chitosan and chitosan/HA composite scaffolds with an appropriate pore size of 40-250 lm proved highly desirable to allow cellular infiltration and tissue in-growth, and eventually shorten healing time and improve clinical outcome. 20, 21 At the same time, the well-developed porous structure of these scaffolds should facilitate their use in delivery of drugs or bioactive molecules via the provision of sustained drug diffusion to the surrounding host tissues through a network of fluid-filled pores and channels. 22, 23 Herein, as a first step to evaluate their potential application as controlled drug delivery devices, a broad-spectrum antibiotic drug was preloaded during the scaffold fabrication, and the in vitro, drug-release profile was investigated. The results demonstrated that the release kinetics of TCH from the porous scaffolds was controlled by varying the HA content. In the present system, the differences in the structural and morphological features of the scaffolds seemed to be the predominant factor determining their drug-release behavior. As presented in Figure 1 , the increase in the HA content decreased the pore size and porosity of the scaffolds, thereby rendering the fluid access more difficult and retarding both the diffusion process and release rate of TCH. In addition, the drug-release rate was also thought to be partially dependent on the hydrolytic behavior of the scaffolds. 24 Although degradation testing was not carried out in this study, it could be inferred from our previous study that the increased HA content would slow down the degradation process of the composites. 11 Thus, the chitosan/HA hybrid scaffolds containing a higher content of HA were expected to have a slower drug-release rate.
After 5 days of release, a certain amount of the loaded drug was still trapped in both the chitosan and hybrid scaffolds. Moreover, the percentage of this residual TCH increased with increasing HA content. This drug fraction was probably bound to the chitosan network via hydrogen bonding and ionic interactions, or absorbed onto the nano-HA particles due to their strong affinity with calcium ions. 25, 26 It was proposed that the remaining drug would only be released in concomitance with the slow scaffold degradation.
Although the drug-release rate of the porous scaffolds could be adjusted by varying their HA content, the initial burst effect and relatively fast release kinetic were difficult to control with these simply structured scaffolds. The fine control of drug-release kinetics requires the successful design of carriers with particular structures. 27, 28 Therefore, to obtain a tailored, drug-release pattern, a gradient-based strategy was developed to optimize the structure of the porous 3-D hybrid scaffolds. As illustrated in Figure 6 , the gradient, drug-free coating layers substantially decreased the initial burst effect as well as the overall drug-release rate, thus allowing delivery of TCH in a controlled manner. In addition, such a designed drug carrier with gradient structure and drug concentration has the potential to act as a reservoir-type drug delivery device wherein the drugrelease rate is controlled by adjusting the coating layer thickness. This potential, which is associated with the design of functional scaffolds to obtain control over drugrelease kinetics for specific applications, remains an area for future research.
The rapid development of biomedical engineering over the last few decades has depended greatly on the successful optimization of the existing materials in terms of their structural design and functional extension. [29] [30] [31] [32] Chitosan/ HA composites have been primarily developed as a bioac-tive substrate to guide bone or tooth tissue regeneration. However, in this study, their role was successfully extended to serve as a temporary carrier for controlled drug release. Moreover, in view of their great potential for the controlled release of antibiotic drugs, the functional scaffolds developed here also show promise for application to the delivery of various bioactive molecules, such as growth factors and other proteins for enhanced tissue regeneration. Furthermore, the methodology developed in this study is promisingly applicable to develop other biomimetic nanocomposites as potential drug-delivery systems.
CONCLUSIONS
Three-dimensional porous chitosan/HA scaffolds containing TCH as a model drug were prepared by mixing their coprecipitates with the drug and freeze-drying. The phase, morphology and in vitro drug-release behavior of the scaffolds were investigated. A well-developed porous structure of the scaffolds consisted of open pore channels and an interconnected framework. The in vitro, drug-release test showed that a burst release of TCH from the porous scaffold occurred during the first 2 h, after which the drug was released at a much slower rate for up to 120 h. The release rate was reduced with increasing HA content. Based on this demonstrated potential, a porous, nondrug-loaded layer was coated on the scaffolds to create a drug concentration gradient, which significantly decreased the burst effect and prolonged the release kinetics. Furthermore, a dense and drugfree layer was successively formed on the aforementioned porous coating layer to produce a functional scaffold with a porous core/dense shell structure. This structure gradient in the scaffolds avoided the initial drug burst and ensured an approximately linear release of drugs over 240 h.
